CNBP welcomes its newest researcher to the team, Dr Thomas Avery who is based at the University of Adelaide.
Thomas was awarded a PhD in chemistry by The University of Adelaide in 2002 and completed post-doctoral positions at The University of Oxford (England) with Dr David Hodgson and The University of Adelaide with Dr Dennis Taylor. During his post-doctoral tenures, he developed a strong publication record in leading organic chemistry journals typically focused on probing the scope, mechanism and application of novel chemical reactions.
Transitioning to industry in 2008, Thomas contributed to new drug development for Adelaide based company Bionomics Ltd, as a Senior Research Scientist in the chemistry division. Bionomics provided him the opportunity to work on a diverse set of projects developing drug candidates in cancer therapeutics and for CNS indications. Most notably, he was chemistry lead for the program that led to the cognition/Alzheimer’s disease collaboration with Merck Sharp and Dohme (MSD) and more recently the pain collaboration, also partnered with MSD.
Thomas has now returned to an academic research role as a CNBP Research Fellow in Professor Andrew Abell’s group.
Building on his medicinal chemistry background he will work on projects to create potential medicaments and biosensors within the Centre. More specifically, his first project is to create Bortezomib-like proteasome inhibitors with improved selectivity and targeted mode of action employing photo-switchable moieties.
A big welcome to the CNBP team Thomas!